19 June 2013
Keywords: alnylam, loss, rockets, expenses, usa-based, rnai, therapeutics
Article | 11 May 2009
USA-based RNAi therapeutics company Alnylam's first-quarter loss rocketed as higher R&D costs failed to be balanced by increased revenue.
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
11 May 2009
13 May 2009
© 2013 thepharmaletter.com